How to buy Anika Therapeutics (ANIK) stock

Anika Therapeutics, Inc is a biotechnology business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Anika Therapeutics employs 277 staff and has a trailing 12-month revenue of around 0.00.

Anika Therapeutics stock price (NASDAQ: ANIK)

Use our graph to track the performance of ANIK stocks over time.

Anika Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$46.65
52-week range	$32.04 - $48.37
50-day moving average	$43.16
200-day moving average	$40.49
Wall St. target price	$51.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.79

Buy Anika Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Anika Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Anika Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anika Therapeutics price performance over time

Historical closes compared with the close of $46.65 from 2021-05-28

1 week (2021-07-17)	N/A
1 month (2021-06-28)	4.41%
3 months (2021-04-28)	14.28%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

Is Anika Therapeutics under- or over-valued?

Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Anika Therapeutics's PEG ratio

Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 10.17. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Anika Therapeutics's EBITDA

Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.1 million.

The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.

Anika Therapeutics financials

Revenue TTM	$129.4 million
Gross profit TTM	$80.1 million
Return on assets TTM	-0.84%
Return on equity TTM	-9.45%
Profit margin	-20.83%
Book value	$19.26
Market capitalisation	$575.5 million

TTM: trailing 12 months

Shorting Anika Therapeutics shares

There are currently 1.4 million Anika Therapeutics shares held short by investors – that's known as Anika Therapeutics's "short interest". This figure is 8.4% down from 1.5 million last month.

There are a few different ways that this level of interest in shorting Anika Therapeutics shares can be evaluated.

Anika Therapeutics's "short interest ratio" (SIR)

Anika Therapeutics's "short interest ratio" (SIR) is the quantity of Anika Therapeutics shares currently shorted divided by the average quantity of Anika Therapeutics shares traded daily (recently around 130808.80077369). Anika Therapeutics's SIR currently stands at 10.34. In other words for every 100,000 Anika Therapeutics shares traded daily on the market, roughly 10340 shares are currently held short.

However Anika Therapeutics's short interest can also be evaluated against the total number of Anika Therapeutics shares, or, against the total number of tradable Anika Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anika Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Anika Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1002% of the tradable shares (for every 100,000 tradable Anika Therapeutics shares, roughly 100 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Anika Therapeutics.

Find out more about how you can short Anika Therapeutics stock.

Anika Therapeutics share dividends

We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.

Anika Therapeutics share price volatility

Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $32.04 up to $48.37. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 1.2247. This would suggest that Anika Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Anika Therapeutics overview

Anika Therapeutics, Inc. , together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

What percentage of Anika Therapeutics is owned by insiders or institutions?
Currently 0.809% of Anika Therapeutics shares are held by insiders and 96.065% by institutions. How many people work for Anika Therapeutics?
Latest data suggests 277 work at Anika Therapeutics. When does the fiscal year end for Anika Therapeutics?
Anika Therapeutics's fiscal year ends in December. Where is Anika Therapeutics based?
Anika Therapeutics's address is: 32 Wiggins Avenue, Bedford, MA, United States, 01730 What is Anika Therapeutics's ISIN number?
Anika Therapeutics's international securities identification number is: US0352551081 What is Anika Therapeutics's CUSIP number?
Anika Therapeutics's Committee on Uniform Securities Identification Procedures number is: 035255108